Poornima Pandellapalli, MD
Medical Oncology · Washington, DCNPI 1205933850
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $78 and has fallen 62.9% since, to $29 in 2022. That places this record below the midpoint for medical oncology clinicians in DC, where the typical reported total is $1,820.
Across 11 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$25
- Amgen$20
- Pharmacyclics LLC, An Abbvie Company$18
- E.r. Squibb & Sons, L.L.C.$18
- EMD Serono, Inc.$16
- Teleflex LLC$16
- plus $68 from 5 others
What the payments were for
- Food & beverage$181100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 1 | $25 |
| Amgen | 1 | $20 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| EMD Serono, Inc. | 1 | $16 |
| Teleflex LLC | 1 | $16 |
| Incyte Corporation | 1 | $16 |
| Merck | 1 | $14 |
| Seagen Inc. | 1 | $13 |
| GSK | 1 | $13 |
| Exelixis Inc. | 1 | $12 |
How this compares
$181 in reported general payments places this provider in the 20th percentile of 29 medical oncology providers in District of Columbia.
See all medical oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 17 | $20,498 |
| EliquisApixaban | 21 | $16,384 |
| Oxycodone Hcl | 13 | $1,109 |
| Dexamethasone | 23 | $350 |
| Anastrozole | 11 | $280 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 17 | $252 |
| Hydroxyurea | 11 | $234 |
| Prochlorperazine Maleate | 16 | $229 |
| Letrozole | 15 | $207 |
| Ondansetron Hcl | 15 | $108 |
| Olanzapine | 15 | $93 |
| Prednisone | 11 | $54 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Washington
- Nancy DawsonWashington$1.7M
- Joshua ReussWashington$218K
- Pashna MunshiWashington$189K
- Michael PishvaianWashington$147K
- Kieron DunleavyWashington$139K
- Asim AminWashington$120K
- Mitchell SmithWashington$41K
- Channing PallerWashington$33K
- Solmaz SahebjamWashington$31K
- Khaled El-ShamiWashington$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.